Rittershaus Charles W
AVANT Immunotherapeutics Inc., 119 Fourth Ave., Needham, Massachusetts 02494, USA.
World J Surg. 2007 Apr;31(4):690-4. doi: 10.1007/s00268-006-0759-0.
Over the last 50 years, several attempts have been made to harness the power and economy of vaccines in the fight against cardiovascular disease. Vaccines directed to lipoproteins, cholesterol itself, and molecules involved in cholesterol metabolism have all demonstrated success in modifying progression of disease in animal models of atherosclerosis. One vaccine that elicits antibodies to cholesteryl ester transfer protein has also progressed into the realm of human clinical testing. This review summarizes the published scientific work describing the various approaches that have been tried, their strengths and weaknesses, and where this field may go in the future.
在过去50年里,人们多次尝试利用疫苗的功效和经济性来对抗心血管疾病。针对脂蛋白、胆固醇本身以及参与胆固醇代谢的分子研发的疫苗,均已在动脉粥样硬化动物模型中成功改变疾病进展。一种能引发针对胆固醇酯转运蛋白抗体的疫苗也已进入人体临床试验阶段。本综述总结了已发表的科学研究,介绍了各种已尝试的方法、它们的优缺点以及该领域未来的发展方向。